Business Wire

IL-NIELSENIQ

17.7.2024 15:01:33 CEST | Business Wire | Press release

Share
NielsenIQ (NIQ) powered by CGA strengthens On Premise Measurement (OPM) and share tracking services for Beverage Alcohol brands

NIQ powered by CGA is expanding its On Premise Measurement (OPM) globally. On Premise accounts for 61% of global beverage alcohol value sales, making it vital for brand owners to continue to invest in the channel. On Premise provides an important platform for building brand equity and long-term consumer loyalty. This, in part, is demonstrated by the fact that beverage alcohol brands have overall been less impacted by the threat of private label than other FMCG categories. The volume of private labels in Off Premise accounts for less than 10% of total sales, (a figure far lower than the equivalent for other FMCG categories).

Innovative serve strategies and activations which connect with consumers and ensure elevated quality will be key to maintaining a positive perception of value among consumers, as well as building long term success for Beverage Alcohol brands and On Premise alike.

Key Highlights of the NIQ On Premise Study powered by CGA includes:

  • 83% of global LDA* consumers have visited On Premise in the last 3 months, with 62% visiting weekly
  • Visitation has remained stable globally, despite most consumers feeling financially worse off than they were last year.
  • On Premise plays a vital role in facilitating connections with friends and loved ones, with 3 of the fastest growing reasons for visit being - Connecting with family and friends, to celebrate and to have fun.
  • On Premise accounts for 61% of global beverage alcohol value sales (excluding wine).
  • Although visits are stable, global On Premise sales of beer, malt beverages and cider volume sales have fallen by 4.0% in the last 12 months. Spirits have fallen by 7.6%.
  • Gen Z and younger Millennials (to age 34) are most likely to increase their visits to On Premise over the next 3 months with a net increase of 27pp vs 14pp for all On Premise visitors.

*LDA – Legal Drinking Age

The OPM solution supports businesses’ strategies to grow sales against a backdrop of changing On Premise preferences, including a moderation in alcohol intake. Alongside OPM, NIQ conducted a study of 30,000 On Premise consumers across 38 markets to reveal that even though consumer visits to the On Premise remain high, consumers’ relationship with alcohol is mixed, with more than a third (37%) of consumers now drinking less alcohol than they were 12 months ago. Generation X and infrequent visitors to the On Premise are most likely to be cutting their alcohol intake.

NIQ’s On Premise Measurement (OPM) service drills deep into data to spotlight the impact of these consumer trends on category performance. Global beer, malt beverages and cider sales by volume have fallen by 4.0% in the last 12 months, and higher prices have led to a 0.4% increase by value. By contrast, spirits have lost 7.6% and 3.4% by volume and value respectively. There have been particularly sharp drops in brandy, rum, and gin sales in key markets, while others including tequila and vodka have performed better.

Phil Tate, Managing Director for Global Clients at NIQ said: “Our research shows how the role of the On Premise is evolving rapidly around the world. Alcohol consumption may be falling, but bars, pubs and restaurants are still pivotal to consumers lives. While moderation is clearly impacting Beverage Alcohol performance, people’s shifting drinks preferences are opening new opportunities in other categories. On Premise remains a vital channel for growing brand equity, and association with memorable moments here is a powerful way to secure trial and loyalty. With some consumer cost pressures easing and younger adults particularly engaged, there is significant headroom for growth in the months and years ahead.”

Despite volume declines, there is reason to be optimistic as people remain eager to go out and are set to increase their spending in the second half of 2024. On Premise plays a significant role in consumers lives as a destination for bringing together loved ones and enables brands to create meaningful connections with consumers to build brand loyalty.

A quarter (26%) of global consumers surveyed by NIQ say they will raise the frequency of their visits to On Premise over the next three months—more than double the number (12%) who plan to go out less often. Gen Z are significantly more likely to increase their visits.

About OPM

NIQ’s OPM service measures brand and category sales performance in On Premise across multiple territories. OPM enables brand owners to uncover growth driving market trends, evaluate brand performance and track share, as well as identify headroom opportunities and assess competition.

OPM is powered by On Premise experts CGA, which was acquired by NIQ in 2022. OPM has been refined by CGA over many years in the UK and US, delivering in-depth analysis of sales, distribution and pricing by region and channel that help brands to win in multiple markets. It has now been expanded to key countries including Australia, Canada, Germany and France, with South Korea to follow soon.

For more information about NIQ powered by CGA’s OPM service and other solutions in international markets, click here.

About NIQ:

NielsenIQ (NIQ) is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in more than 95 countries covering 97% of GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240717934770/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye